|

Depemokimab Clinical Trials

5 actively recruiting trials across 5 locations

▲ +1 trial since June 2026

Also known as: GSK3511294

Pipeline

Phase 3: 5

Top Sponsors

  • GlaxoSmithKline5

Indications

  • Pulmonary Disease, Chronic Obstructive3
  • COPD3
  • Asthma2

Sheffield, Alabama1 trial

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

GSK Investigational Site

Phase 3

Newport Beach, California1 trial

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

GSK Investigational Site

Phase 3

Brooksville, Florida1 trial

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

GSK Investigational Site

Phase 3

Doral, Florida1 trial

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

GSK Investigational Site

Phase 3

Loxahatchee Groves, Florida1 trial

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

GSK Investigational Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.